Domů › Rakovina močového měchýře › Texas › Dallas
Klinické studie Rakovina močového měchýře v Dallas, TX
27 studií pro Rakovina močového měchýře hledá účastníky v lokalitách v Dallas a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Probíhá náborFáze 2
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Enfortumab Vedotin and Stereotactic Radiation for Localized Bladder Cancer
Probíhá náborFáze 1/2
- UT Southwestern Medical Center, Dallas
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Probíhá náborFáze 2
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Probíhá náborFáze 1
- Cancer Center Outpatient Building, Dallas
- The University of Texas Southwestern Medical Center, Dallas
- UT Southwestern Medical Center - West Campus Building, Dallas
- a dalších 2
DESTINY-PANTUMOUR04
Probíhá náborObservační studie
- Research Site, Dallas
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Probíhá náborFáze 3
- Parkland Health and Hospital System, Dallas
- UT Southwestern Medical Center, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Probíhá náborObservační studie
- UT Southwestern Medical Center, Dallas
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Probíhá náborFáze 2
- Urology Clinics of North Texas, PLLC, Dallas
- UT Southwestern Medical Center, Dallas
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
Probíhá náborObservační studie
- University of Texas Southwestern Medical Center, Dallas
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Probíhá náborFáze 1
- University of Texas Southwestern, Dallas
- Texas Oncology, P.A, Dallas
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Probíhá náborFáze 2/3
- Research Site, Dallas
Measuring Surgical Recovery After Radical Cystectomy
Probíhá náborObservační studie
- University of Texas - Southwestern, Dallas
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Probíhá náborFáze 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Probíhá náborFáze 1/2
- UT Southwestern Medical Center, Dallas
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Probíhá náborFáze 2
- Baylor Scott & White Research Institute, Dallas
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Probíhá náborFáze 3
- Research Site, Dallas
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Probíhá náborFáze 2
- Baylor Scott and White Research Institute, Dallas
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Probíhá náborFáze 1
- NEXT Dallas, Dallas
Predicting BCG Response
Probíhá náborObservační studie
- University of Texas Southwestern, Dallas
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Probíhá nábor
- UT Southwestern Medical Center, Dallas
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer
Probíhá náborObservační studie
- UT Southwestern Medical Center, Dallas
Bladder Cancer Screening Trial
Probíhá nábor
- University of Texas Southwestern Medical Center, Dallas
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Probíhá náborFáze 1/2
- NEXT Oncology - Dallas, Dallas
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Probíhá náborFáze 1
- Mary Crowley Cancer Research, Dallas
- Baylor University Medical Center, Dallas
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Probíhá náborObservační studie
- UT Southwestern Medical Center at Dallas, Dallas
Blue Light Cystoscopy With Cysview® Registry
Probíhá náborObservační studie
- UT Southwestern, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Probíhá náborObservační studie
- Massive Bio SYNERGY-AI site, Dallas
Studie Rakovina močového měchýře v jiných městech
- New York City, NY35 studií
- Nashville, TN31 studií
- Houston, TX31 studií
- Boston, MA26 studií
- Washington, DC26 studií
- Los Angeles, CA24 studií
- Baltimore, MD24 studií
- St. Louis, MO22 studií
- Philadelphia, PA21 studií
- Seattle, WA21 studií
- Edison, NJ21 studií
- Chicago, IL21 studií
Další studie v Dallas
- Rakovina prsu55 studií
- Nemalobuněčný plicní karcinom52 studií
- Metastatický karcinom42 studií
- Srdeční selhání42 studií
- Rakovina (všechny typy)37 studií
- Rakovina prostaty36 studií
- Kolorektální karcinom33 studií
- Obesity30 studií
- Rakovina vaječníků28 studií
- Rakovina plic27 studií
- Rakovina endometria24 studií
- Kardiovaskulární onemocnění23 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.